#novo nordisk

تتعامل نوڤو نورديسك مع مغادرتين في وقت واحد، بما في ذلك تقاعد رائدة GLP-1 لوتّه بييرّيه كنودسن وانتقال إحدى قيادات السمنة إلى بوهرينغر إنغلهيم.

Novo Nordisk and Hims & Hers have ended their legal battle with a partnership that could reshape the booming compounded GLP-1 drug market and limit cheaper alternatives.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.